Standout Papers
- Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). (2022)
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study (2012)
Immediate Impact
15 by Nobel laureates 16 from Science/Nature 96 standout
Citing Papers
Targeted protein degradation: from mechanisms to clinic
2024 Standout
Therapeutic resistance to anti-oestrogen therapy in breast cancer
2023 Standout
Works of Haolan Lu being referenced
ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
2022
Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
2022 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Haolan Lu | 1165 | 480 | 366 | 465 | 33 | 1.6k | |
| Dmitri Pavlov | 1126 | 272 | 428 | 709 | 40 | 1.8k | |
| Philip D. Leming | 1475 | 567 | 462 | 596 | 21 | 1.8k | |
| Juan Martín-Liberal | 1075 | 416 | 340 | 405 | 83 | 1.5k | |
| Fabio Conforti | 1106 | 507 | 377 | 373 | 78 | 1.8k | |
| Jeffrey P. Hodge | 1229 | 552 | 782 | 393 | 39 | 2.2k | |
| Alexander Luft | 1447 | 695 | 282 | 484 | 21 | 1.7k | |
| Pallavi S. Mishra‐Kalyani | 844 | 537 | 312 | 188 | 49 | 1.4k | |
| S.H. Goey | 750 | 254 | 269 | 398 | 31 | 1.2k | |
| Jacopo Pigozzo | 1633 | 457 | 575 | 650 | 56 | 2.0k | |
| Kristen A. Marrone | 1395 | 719 | 439 | 403 | 71 | 1.9k |
All Works
Loading papers...